Breast cancer treatment for elderly women: a systematic review
|
|
- Kathryn Dalton
- 2 years ago
- Views:
Transcription
1 Breast cancer treatment for elderly women: a systematic review Gerlinde Pilkington Rumona Dickson Anna Sanniti Funded by the NCEI and POI
2 Elderly people less likely to receive chemotherapy than younger people with cancer Uncertainties as to whether elderly people can tolerate chemotherapy Elderly people underrepresented in clinical trials Lack of data on outcomes for elderly people treated with chemotherapy Background Funded by the National Cancer Equality Initiative (NCEI) and the Pharmaceutical Oncology Initiative (POI) Six systematic reviews investigating the efficacy and tolerability of chemotherapy to treat elderly people with: Breast cancer Lung cancer Colorectal Cancer Renal cell carcinoma Chronic myeloid leukaemia Non-Hodgkin s lymphoma 1
3 Aims and objectives Aim To systematically review the evidence for the clinical effectiveness and tolerability of chemotherapy regimens used to treat breast cancer in elderly people Objectives summarise the relevant evidence related to clinical effectiveness and tolerability to treatment explore the implications of these findings for practice and service provision in order to disseminate accessible information to clinicians inform future decisions on research priorities through the identification of gaps and weaknesses in the available evidence 2
4 Methods Searching MEDLINE, EMBASE, The Cochrane Library, Web of Knowledge January 2000 to May 2013 Exported to EndNote, duplicates removed Screening Two reviewers screen titles and abstracts independently Potentially relevant studies obtained Selection Two reviewers independently assess studies for inclusion Studies not meeting inclusion criteria excluded Data extraction Data were extracted on study design, population characteristics and outcomes by one reviewer, checked for accuracy by a second RCTs were quality assessed 3
5 Inclusion criteria Patient population Interventions Comparators Older/elderly people (as defined in study) treated for breast cancer Any chemotherapy (all lines of treatment) An alternative chemotherapy Best supportive care Outcomes Efficacy outcomes: Overall survival Response rates Time to event measures Tolerability outcomes: Adverse events Measures of tolerability Other outcomes: Quality of life (QoL) Comprehensive geriatric assessment (CGA) Study design Other considerations RCTs, cohort studies and retrospective studies of databases and registries Studies that reported sub-group analyses of elderly people in the abstract were included Only studies published post-2000 in English (or English abstract) were included 4
6 Tolerability measures Adherence to treatment Cycles delivered per patient How many patients completed treatment Relative dose intensity (RDI) Treatment discontinuations Discontinuations due to toxicity Discontinuations due to progressive disease Withdrawal of consent Dose modifications Treatment modifications or interruptions due to toxicity 5
7 Results 8 RCTs 5 sub-group analyses 5716 references identified 5548 references after deduplication 147 references included at stage references excluded at stage 1 91 references (75 studies) included at stage 2 56 references excluded at stage 2 7 pooled analyses 3 prospective comparative cohorts 32 prospective single cohorts 20 retrospective data studies 6
8 Results cont. Breakdown of studies by disease stage Mixed Locally advanced/metastatic breast cancer Early breast cancer Retrospective data Single cohorts Comparative cohorts 1 2 Pooled analyses 3 4 Sub-group analyses 2 3 RCT 4 7
9 Study characteristics Size 48 studies included less than 100 patients 27 studies included more than 100 patients Location 38 studies were multicentre 37 studies were based in single centres 45 studies had centres in Europe Funding 53 studies did not report funding source 15 studies funded by pharmaceutical companies 7 studies funded by research grants 8
10 Patient characteristics Age The definition of elderly varied from 55 years to 75 years The median age of patients across studies ranged from 61 to 78 years Performance status The majority of patients in each study had a performance status of 0-1 Single cohorts included patients with a higher performance status of 2 9
11 PFS/TTP Efficacy outcomes Overall survival Overall response rates Trend for younger patients to fare better Elderly patients derived benefit No statistically significant comparisons Elderly patients gained slightly less benefit Differences were small No statistically significant comparisons Results similar for both groups No statistically significant comparisons *PFS=progression free survival; TTP=time to progression 10
12 Tolerability evidence Treatment adherence Discontinuations Modifications Grade 3-4 adverse events Broadly similar results for both groups for RDI Younger patients generally had higher rates of treatment completion No statistically significant differences reported Trend for higher discontinuation rates in elderly patients Most discontinuations due to toxicity or progressive disease Elderly patients were more likely to have dose modifications Common causes for dose modification was haematological toxicity Trend for higher rates of adverse events in elderly patients Statistically significant results for higher rates of grade 3-4 haematological adverse events in elderly patients 11
13 Quality of life Quality of life results reported in 13/75 studies (3 RCTs, 1 comparative cohort, 8 single cohorts and 1 retrospective study) 11 different quality of life tools used across studies 4 studies reported completion rates for questionnaires Results broadly suggest no significant changes in quality of life throughout treatment 12
14 Comprehensive geriatric assessment Tools used Purpose of tool Activities of Daily Living (ADL) Instrumental ADL (IADL) Vulnerable Elders Survey-13 (VES-13) Charlson Comorbidity Index (CCI) Geriatric depression scale (GDS) Mini-Mental Status (MMS) Karnofsky performance status (KPS) Cumulative Illness Rating Scale for Geriatrics (CIRS-G) Multidimensional Geriatric Assessment (MGA) To assess eligibility for study entry = 1 study As an outcome measure (changes from baseline scores recorded at intervals) = 10 studies 13
15 Conclusions Chemotherapy for elderly people with breast cancer is: o A feasible treatment option o Effective and gives survival benefit o Safe and can be tolerated o Comes with an increased risk of toxic effects Age should not be a barrier to either receiving treatment or being eligible for clinical trials 14
16 Future research Few quality RCTs treating elderly-only population Conduct more clinical trials with an elderlyonly population Include more elderly people in high quality clinical trials RCTs report different outcome measures which cannot be synthesised Implement consistent use of measures to enable meaningful synthesis Trials design to plan collection of supplementary data, e.g. tolerability, QoL No standardised, widely used tools for QoL or CGA Develop and test specific tools for QoL and CGA Implement the standard use of CGA and QoL in clinical trials 15
17 Question time If you require any further information, please get in touch: Gerlinde Pilkington Liverpool Reviews and Implementation Group (LRiG) University of Liverpool Room 2.21a Whelan Building The Quadrangle Brownlow Hill Liverpool L69 3GB Tel: Website: 16
18 Quality assessment We used criteria based on the Centre for Reviews and Dissemination guidance 2 trials were reported as abstracts, therefore not quality assessed Three of the included RCTs were assessed as adequately randomised No trials considered as having adequate concealment of allocation* All trials clearly reported the number of participants randomised Baseline characteristics were presented in all trials Baseline comparability achieved in 7/8 trials All trials reported reasons for withdrawals * A technique used to prevent selection bias by concealing the allocation sequence from those assigning participants to intervention groups Centre for Reviews and Dissemination (CRD). CRD's guidance for undertaking reviews in healthcare: Systematic Reviews (3rd Edition). York: CRD, University of York; 2008; Available from: 17
19 Strengths and limitations Strengths: Comprehensive evidence base Focus on tolerability meaningful for clinicians Enabled comparisons between elderly/younger Limitations: Broad inclusion criteria = heterogeneity Unable to conduct statistical analyses 18
Best supportive care: Do we know what it is?
Best supportive care: Do we know what it is? Angela Boland Rumona Dickson Barbara Jack James Stevenson Edge Hill University Faculty of Health www.liv.ac.uk/lrig Collaborative partners Liverpool Reviews
Clinical Trials in Geriatric Oncology. Anita O Donovan Assistant Professor, Trinity College Dublin &
Clinical Trials in Geriatric Oncology Anita O Donovan Assistant Professor, Trinity College Dublin & Chair of the Membership and NR Committee, SIOG Overview The evidence for under recruitment Issues affecting
Simplifying the measurement of co-morbidities and their influence on chemotherapy toxicity
Simplifying the measurement of co-morbidities and their influence on chemotherapy toxicity Dr Rajesh Sinha BSc MBBS MRCP, Clinical Research Fellow in Medical Oncology Brighton and Sussex University Hospitals
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
Recommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality
CHEMO- AND TARGETED THERAPY FOR WOMEN WITH HER2 NEGATIVE (OR UNKNOWN) ADVANCED BREAST Benefit/Harm Evidence Quality 1: Endocrine therapy, rather than chemotherapy, should be offered as the standard firstline
Cochrane Review: Psychological treatments for depression and anxiety in dementia and mild cognitive impairment
23 rd Alzheimer Europe Conference St. Julian's, Malta, 2013 Cochrane Review: Psychological treatments for depression and anxiety in dementia and mild cognitive impairment Orgeta V, Qazi A, Spector A E,
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
What are observational studies and how do they differ from clinical trials?
What are observational studies and how do they differ from clinical trials? Caroline A. Sabin Dept. Infection and Population Health UCL, Royal Free Campus London, UK Experimental/observational studies
Cancer in the aging population: Individualizing pretreatment assessment
Cancer in the aging population: Individualizing pretreatment assessment Heidi D. Klepin, MD, MS Associate Professor of Internal Medicine, Section on Hematology and Oncology Financial Disclosure(s) I have
Are older people receiving cancer drugs?
Are older people receiving cancer drugs? An analysis of patterns in cancer drug delivery according to the age of patient December 2013 1 NHS England INFORMATION READER BOX Directorate Medical Operations
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
DECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
Understanding, appraising and reporting meta-analyses that use individual participant data
Understanding, appraising and reporting meta-analyses that use individual participant data Jayne Tierney, Claire Vale, Maroeska Rovers, Lesley Stewart IPD Meta-analysis Methods Group 21 st Annual Cochrane
Evidence-based Synthesis Program. October 2012
Department of Veterans Affairs Health Services Research & Development Service Effects of Health Plan-Sponsored Fitness Center Benefits on Physical Activity, Health Outcomes, and Health Care Costs and Utilization:
Sonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995
Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,
Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE. Bortezomib for the treatment of multiple myeloma patients
Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE Bortezomib for the treatment of multiple myeloma patients Produced by Southampton Health Technology Assessments
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for
Can I have FAITH in this Review?
Can I have FAITH in this Review? Find Appraise Include Total Heterogeneity Paul Glasziou Centre for Research in Evidence Based Practice Bond University What do you do? For an acutely ill patient, you do
Systematic Reviews. knowledge to support evidence-informed health and social care
Systematic Reviews knowledge to support evidence-informed health and social care By removing uncertainties in science and research, systematic reviews ensure that only the most effective and best-value
Critical appraisal of systematic reviews
Critical appraisal of systematic reviews Abalos E, Carroli G, Mackey ME, Bergel E Centro Rosarino de Estudios Perinatales, Rosario, Argentina INTRODUCTION In spite of the increasingly efficient ways to
A Guide to Clinical Trials
A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.
Summary 1. Comparative-effectiveness
Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately
Does Selenium protect against lung cancer? Do Selenium supplements reduce the incidence of lung cancer in healthy individuals?
Does Selenium protect against lung cancer? Do Selenium supplements reduce the incidence of lung cancer in healthy individuals? Alexander Blakes and Eleanor Brunt October 2014 The question Mr Wilson s father
Form B-1. Inclusion form for the effectiveness of different methods of toilet training for bowel and bladder control
Form B-1. Inclusion form for the effectiveness of different methods of toilet training for bowel and bladder control Form B-2. Assessment of methodology for non-randomized controlled trials for the effectiveness
What factors determine poor functional outcome following Total Knee Replacement (TKR)?
Specific Question: What factors determine poor functional outcome following Total Knee Replacement ()? Clinical bottom line All groups derived benefit from undergoing a, reviews suggests that the decision
STRATEGIES FOR ASSESSING THE PATIENT-LEVEL ECONOMIC IMPACT OF CANCER DIAGNOSIS
Cumulative % Increase 5/20/2015 STRATEGIES FOR ASSESSING THE PATIENT-LEVEL ECONOMIC IMPACT OF CANCER DIAGNOSIS ISPOR 20 th Annual International Meeting -- Philadelphia, PA May 20 th 2015 Workshop Moderators:
Treatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)
Overview Amy Davidoff, Ph.D., M.S. Associate Professor Pharmaceutical Health Services Research Department, Peter Lamy Center on Drug Therapy and Aging University of Maryland School of Pharmacy Clinical
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
Clinical bottom line. For more detailed evidence on the effectiveness of injections for tennis elbow, please see the CAT on:
Short Question: Specific Question: In patients presenting with acute or chronic tendinopathies, what is the incidence of harm for those receiving steroid injections compared to those receiving usual care?
Laura Biganzoli Oncologia Medica Nuovo Ospedale di Prato Istituto Toscano Tumori
EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nabpaclitaxel in elderly patients with advanced breast cancer Laura Biganzoli Oncologia Medica
What s new in cancer. NHMRC Evidence hierarchy. Evidence Based Guidelines 12/06/2013. Level I: systematic review of all RCTs
What s new in cancer treatment? Dr Liz Isenring, AdvAPD Email: e.isenring@uq.edu.au Clinical Academic Fellow, Princess Alexandra Hospital Conjoint Senior Lecturer University of Queensland, Australia Evidence
EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
33 % of whiplash patients develop. headaches originating from the upper. cervical spine
33 % of whiplash patients develop headaches originating from the upper cervical spine - Dr Nikolai Bogduk Spine, 1995 1 Physical Treatments for Headache: A Structured Review Headache: The Journal of Head
Alexandra Bargiota Assist. Prof. in Endocrinology University Hopsital of Larissa Thessaly, Greece. www.united4health.eu
Applying Evidence-Based Medicine with Telehealth the clinician view Assessing the impact of telehealth/telemedicine either via an RCT or an observational study the voice of a clinician Alexandra Bargiota
Secondary Uses of Data for Comparative Effectiveness Research
Secondary Uses of Data for Comparative Effectiveness Research Paul Wallace MD Director, Center for Comparative Effectiveness Research The Lewin Group Paul.Wallace@lewin.com Disclosure/Perspectives Training:
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
The impact of patient age on clinical decision-making in oncology
The impact of patient age on clinical decision-making in oncology February 2012 DH INFORMATION READER BOX Policy Clinical Estates HR / Workforce Commissioner Development IM & T Management Provider Development
Web appendix: Supplementary material. Appendix 1 (on-line): Medline search strategy
Web appendix: Supplementary material Appendix 1 (on-line): Medline search strategy exp Venous Thrombosis/ Deep vein thrombosis.mp. Pulmonary embolism.mp. or exp Pulmonary Embolism/ recurrent venous thromboembolism.mp.
Using Criteria to Appraise a Meta-analyses
Using Criteria to Appraise a Meta-analyses Paul Cronin B.A., M.B. B.Ch. B.A.O., M.S., M.R.C.P.I.,.F.R.C.R. Department of Radiology, Division of Cardiothoracic Radiology, University of Michigan, Ann Arbor,
Big Data and Oncology Care Quality Improvement in the United States
Big Data and Oncology Care Quality Improvement in the United States Peter P. Yu, MD, FACP, FASCO President, American Society of Clinical Oncology Director of Cancer Research, Palo Alto Medical Foundation
1. Overview of Clinical Trials
1. Overview of Clinical Trials 1.1. What are clinical trials? Definition A clinical trial is a planned experiment which involves patients and is designed to elucidate the most appropriate treatment of
Brief Communications. Awad Mohamed Ahmed, MD. Abstract
Awad Mohamed Ahmed, MD Professor of Medicine, University of Bahr Elghazal, Khartoum, Sudan For correspondence Professor Awad Mohamed Ahmed E-mail: awad.sd@gmail.com Tel.: +249 912344936 Abstract Randomized
REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology)
452 REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology) (See also General Regulations) M.57 Admission requirements To be eligible for admission to the courses
Do Patients of Racial/Ethnic Minority and Lower SES Use Depression Care Management Differently?
Do Patients of Racial/Ethnic Minority and Lower SES Use Depression Care Management Differently? Yuhua Bao, Ph.D. Division of Health Policy, Department of Public Health Weill Cornell Medical College 2009
Dietary treatment of cachexia challenges of nutritional research in cancer patients
Dietary treatment of cachexia challenges of nutritional research in cancer patients Trude R. Balstad 4th International Seminar of the PRC and EAPC RN, Amsterdam 2014 Outline Cancer cachexia Dietary treatment
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2009 June 30, 2010 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for
The European Cancer Rehabilitation Symposium 2014 September 8, 2014. Parallel session: Obesity, physical activity and dietary challenges
The European Cancer Rehabilitation Symposium 2014 September 8, 2014 Parallel session: Obesity, physical activity and dietary challenges PROGRAM, September 8, 13:15 14:15 13:15 Meaningfulness of physical
Cancer Services Coming of Age: Learning from the Improving Cancer Treatment Assessment and Support for Older People Project.
Cancer Services Coming of Age: Learning from the Improving Cancer Treatment Assessment and Support for Older People Project December 2012 Foreword 3 Foreword The Government has set out ambitious plans
Consent for Systemic Anti Cancer Therapy (SACT)
Consent for Systemic Anti Cancer Therapy (SACT) Guidance issued by the National Chemotherapy Board May 2016 Supported by: Contents National Chemotherapy Board 1. Introduction 1.1. Purpose of the guidance
FOCUSSED CLINICAL QUESTION:
The use of a multifactorial falls risk assessment and management plan reduces the risk of falling and the monthly fall rate of older adults, and is the most effective component of a falls prevention programme
National Institute for Health and Clinical Excellence
Comment 1: the draft remit Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer Table of responses to consultee and commentator comments on the draft scope
Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)
Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Key features of RCT (randomized controlled trial) One group (treatment) receives its treatment at the same time another
Is there a place for qualitative research in evidence based medicine? Dr Kate Flemming University of York, UK
Is there a place for qualitative research in evidence based medicine? Dr Kate Flemming University of York, UK YES Questions? For those of you who are still unsure What is the aim of EBM(P)? To reduce uncertainty
Prepared by:jane Healey (Email: janie_healey@yahoo.com) 4 th year undergraduate occupational therapy student, University of Western Sydney
1 There is fair (2b) level evidence that living skills training is effective at improving independence in food preparation, money management, personal possessions, and efficacy, in adults with persistent
Psychological Well-being of Women With Metastatic Breast. Innovative a Community Supportive-Expressive Group in a Community Setting
Psychological Well-being of Women With Metastatic Breast Psychological Cancer in Well-being an Innovative of Women with Supportive-expressive Metastatic Breast Cancer Group in in an Innovative a Community
TAR call-off contract Scope of Work, Templates
NICE TAR Protocol template guide 1. Introduction 1.1 In order to support the National Institute for Health and Clinical Excellence s (NICE) preferred methods 1 a protocol template for Technology Assessment
Current reporting in published research
Current reporting in published research Doug Altman Centre for Statistics in Medicine, Oxford, UK and EQUATOR Network Research article A published research article is a permanent record that will be used
Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013
Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical
When it comes to health
When it comes to health Medical Evidence Matters EASIER, FASTER EVIDENCE-BASED DECISIONS What is Evidence-Based Medicine (EBM)? Evidence-based medicine is the conscientious, explicit and judicious use
IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
The clinical effectiveness and costeffectiveness surgery for obesity: a systematic review and economic evaluation
The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity The clinical effectiveness and costeffectiveness of bariatric (weight loss) surgery for obesity: a systematic
Avastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
Patient Reported Outcomes
Patient Reported Outcomes 16 December 2013, Nottingham Esther van Zuuren Dermatologist, Leiden University Medical Centre Netherlands Patient Reported Outcomes A Patient Reported Outcome (PRO): any aspect
Effective Health Care Program
Comparative Effectiveness Review Number 152 Effective Health Care Program Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer Executive Summary Background Nature and Burden of Nonmetastatic Muscle-Invasive
Guideline Development The American Society of Clinical Oncology
Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary
WRITING A RESEARCH PROTOCOL
WRITING A RESEARCH PROTOCOL Professor Stuart Taylor, University College London Introduction The research protocol is a fundamental part of high quality medical research and radiological research is no
Cancer Australia Supporting cancer clinical trials in Australia Evaluation framework and performance criteria
Cancer Australia Supporting cancer clinical trials in Australia Evaluation framework and performance criteria Background Through the Support for Cancer Clinical Trials program the Australian Government
Hypofractionated radiotherapy for the treatment of early breast cancer: a systematic review. November 2011
Hypofractionated radiotherapy for the treatment of early breast cancer: a systematic review November 2011 Hypofractionated radiotherapy for the treatment of early breast cancer: was developed by: Cancer
18/11/2013. Getting the Searches off to a good start: Scoping the Literature and Devising a Search Strategy
Getting the Searches off to a good start: Scoping the Literature and Devising a Search Strategy Sheila Fisken Liaison Librarian Information Services University of Edinburgh Sheila.Fisken@ed.ac.uk Chaotic
Rapid Critical Appraisal of Controlled Trials
Rapid Critical Appraisal of Controlled Trials Carl Heneghan Dept of Primary Health Care University of Oxford November 23rd 2009 Five steps in EBM 1. Formulate an answerable question 2. Track down the best
Article Four Different Types of Evidence / Literature Reviews
Article Four Different Types of Evidence / Literature Reviews The rapid growth in the number of reviews undertaken can partly be explained by the current emphasis on evidence-based practice. Healthcare
REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology)
463 REGULATIONS FOR THE POSTGRADUATE DIPLOMA IN CLINICAL RESEARCH METHODOLOGY (PDipClinResMethodology) (See also General Regulations) M.57 Admission requirements To be eligible for admission to the courses
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
Clinical Trials. Helpful information and answers for patients
Clinical Trials Helpful information and answers for patients I joined a clinical trial because I want to make it a better world for my daughter and grandchildren. Hopefully, by the time they re old enough
What is critical appraisal?
...? series Second edition Evidence-based medicine Supported by sanofi-aventis What is critical appraisal? Amanda Burls MBBS BA MSc FFPH Director of the Critical Appraisal Skills Programme, Director of
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
Rituximab for the first-line treatment of stage III IV. D Papaioannou,* R Rafia, J Rathbone, M Stevenson, H Buckley Woods and J Stevens
Rituximab for the first-line treatment of stage III IV follicular lymphoma Rituximab for the first-line treatment of stage III IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic
Guidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
Cancer in Ireland 2013: Annual report of the National Cancer Registry
Cancer in 2013: Annual report of the National Cancer Registry ABBREVIATIONS Acronyms 95% CI 95% confidence interval APC Annual percentage change ASR Age standardised rate (European standard population)
Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
Informatics: Opportunities & Applications. Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit
Informatics: Opportunities & Applications Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit Routine Data "routine data" is data collected as byproducts of clinical
Systematic reviews and meta-analysis
Evidence-Based Medicine And Healthcare Singapore Med J 2005 Vol 46(6) : 270 CME Article Systematic reviews and meta-analysis S Green ABSTRACT Systematic reviews form a potential method for overcoming the
Treatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
Screening for psychological distress in inoperable lung cancer patients: an evaluation of the Brief Distress Thermometer (BDT)
Screening for psychological distress in inoperable lung cancer patients: an evaluation of the Brief Distress Thermometer (BDT) K. Sharkey; A. Ugalde; M. Krishnasamy; K. Gough; D. Ball; S. Aranda; P. Schofield
Clinical trial enrollment among older cancer patients
Clinical trial enrollment among older cancer patients Sharon H. Giordano MD, MPH Professor, Health Services Research Mariana Chavez Mac Gregor MD, MSc Assistant Professor, Breast Medical Oncology Department
Major Depressive Disorders Questions submitted for consideration by workshop participants
Major Depressive Disorders Questions submitted for consideration by workshop participants Prioritizing Comparative Effectiveness Research Questions: PCORI Stakeholder Workshops June 9, 2015 Patient-Centered
Adalimumab for the treatment of psoriasis
DOI: 10.3310/hta13suppl2/07 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Adalimumab for the treatment of psoriasis D Turner, J Picot,* K Cooper and E Loveman Southampton Health Technology Assessments
Evidence-based Practice Center Comparative Effectiveness Review Protocol
Evidence-based Practice Center Comparative Effectiveness Review Protocol Project Title: Comparative Effectiveness of Case Management for Adults With Medical Illness and Complex Care Needs I. Background
Radiation Fatigue and the Use of A Nutritional Supplement
Radiation Fatigue and the Use of A Nutritional Supplement Edward H.Gilbert, M.D., Denise Lindley R.N.,BSN,OCN, Michelle Karlin, RN, AOCNP,FNP- BC Northpoint Cancer Center, Dallas Texas and Verity Cancer
Not All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
Drug discontinuation and switching during the Medicare Part D coverage gap
Drug discontinuation and switching during the Medicare Part D coverage gap Jennifer M. Polinski, ScD, MPH William H. Shrank, MD, MSHS; Haiden A. Huskamp, PhD; Robert J. Glynn, PhD, ScD; Joshua N. Liberman,
The Price of Cancer The public price of registered cancer in New Zealand
The Price of Cancer The public price of registered cancer in New Zealand Citation: The Price of Cancer: The public price of registered cancer in New Zealand. Wellington: Ministry of Health. Published in
Supplementary Table 1: Risk of bias in included studies. Blinding of participants and personnel (performance bias)
Random sequence generation (selection bias) Allocation concealment (selection bias) Blinding of participants and personnel (performance bias) Blinding of outcome assessment (detection bias) Incomplete